The positive expression rate of HE4 was 84.62% in the endometrial cancer group, significantly higher than 66.67% in the endometrial atypical hyperplasia group, and 15.00% in the normal endometrium group (P = 0.014, 0.001). Here, WFDC2 is linked to endometrial cancer.